Imprimis Pharmaceuticals Inc Share Price Nasdaq
Stocks
US45323A2015
Pharmaceuticals
| Market Cap | 1.51B 1.3B 1.22B 1.12B 2.1B 143B 2.13B 14.29B 5.61B 71.91B 5.66B 5.54B 238B | P/E 2026 * |
174x | P/E 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.51B 1.3B 1.22B 1.12B 2.1B 143B 2.13B 14.29B 5.61B 71.91B 5.66B 5.54B 238B | EV / Sales 2026 * |
4.33x | EV / Sales 2027 * | 2.91x |
| Free-Float |
84.07% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Imprimis Pharmaceuticals Inc
| 1 day | +0.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 53 | 16/12/2011 |
Andrew Boll
PSD | President | 43 | 20/08/2025 |
Brett Burrell
CMP | Compliance Officer | - | 30/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Baum
CHM | Chairman | 53 | 18/08/2021 |
Perry Sternberg
BRD | Director/Board Member | 57 | 30/03/2022 |
Adrienne Graves
BRD | Director/Board Member | 71 | 25/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | +11.11% | - | - | 1.51B | |
| -0.52% | +3.21% | +85.02% | +161.12% | 1,057B | |
| +0.88% | +1.13% | +51.13% | +49.76% | 625B | |
| +0.89% | -1.95% | +23.73% | +63.67% | 435B | |
| +0.71% | +3.87% | +47.45% | +38.68% | 363B | |
| +0.64% | -0.49% | +35.39% | +40.21% | 296B | |
| +0.39% | -5.83% | +8.64% | +9.28% | 249B | |
| +1.51% | +6.69% | +44.34% | +62.47% | 222B | |
| +3.92% | -0.46% | -1.21% | -44.09% | 209B | |
| +1.80% | +2.30% | +20.79% | +65.13% | 165B | |
| Average | +1.26% | +0.87% | +35.03% | +49.58% | 402.31B | |
| Weighted average by Cap. | +1.12% | +1.22% | +48.34% | +75.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 348M 301M 281M 258M 486M 33.16B 493M 3.3B 1.3B 16.62B 1.31B 1.28B 54.95B | 517M 448M 418M 383M 721M 49.25B 733M 4.9B 1.92B 24.68B 1.94B 1.9B 81.61B |
| Net income | 9.18M 7.94M 7.42M 6.8M 12.8M 874M 13M 87.02M 34.15M 438M 34.48M 33.72M 1.45B | 93.99M 81.3M 75.92M 69.65M 131M 8.94B 133M 891M 350M 4.48B 353M 345M 14.82B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
